Background-Studies of ≤15 atrial fibrillation (AF) patients have identified atrial-specific mutations within connexin genes, suggesting that somatic mutations may account for sporadic cases of the arrhythmia. We sought to identify atrial somatic mutations among patients with and without AF using targeted deep next-generation sequencing of 560 genes, including genetic culprits implicated in AF, the Mendelian cardiomyopathies and channelopathies, and all ion channels within the genome. Methods and Results-Targeted gene capture and next-generation sequencing were performed on DNA from lymphocytes and left atrial appendages of 34 patients (25 with AF). Twenty AF patients had undergone cardiac surgery exclusively for pulmonary vein isolation and 17 had no structural heart disease. Sequence alignment and variant calling were performed for each atrial-lymphocyte pair using the Burrows-Wheeler Aligner, the Genome Analysis Toolkit, and MuTect packages. Next-generation sequencing yielded a median 265-fold coverage depth (interquartile range, 64-369). Comparison of the 3 million base pairs from each atrial-lymphocyte pair revealed a single potential somatic missense mutation in 3 AF patients and 2 in a single control (12 versus 11%; P=1). All potential discordant variants had low allelic fractions (range, 2.3%-7.3%) and none were detected with conventional sequencing. Conclusions-Using high-depth next-generation sequencing and state-of-the art somatic mutation calling approaches, no pathogenic atrial somatic mutations could be confirmed among 25 AF patients in a comprehensive cardiac arrhythmia genetic panel. These findings indicate that atrial-specific mutations are rare and that somatic mosaicism is unlikely to exert a prominent role in AF pathogenesis. (Circ Cardiovasc Genet. 2015;8:50-57.
A trial fibrillation (AF) is the most common sustained cardiac arrhythmia, and affected patients experience an increased risk of heart failure, stroke, and death. 1, 2 Despite its clinical importance, current treatment strategies for the arrhythmia, including both antiarrhythmic drugs and catheter ablation, have relatively modest long-term efficacy. 3, 4 The lack of definitive therapies for AF likely stems from a limited understanding of its underlying pathophysiology, emphasizing a need for novel insights. 5 Recent work has increasingly highlighted a genetic contribution to the arrhythmia, especially when AF occurs in the absence of structural heart disease. [6] [7] [8] [9] [10] [11] [12] [13] [14] 
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Although a positive family history of the arrhythmia is a major risk factor for AF in the absence of overt cardiovascular disease, 15 a substantial proportion of cases are sporadic. 16 Given that these cases develop in the absence of identifiable risk factors, it is still probable that genetics play a role. The apparent lack of family history may be secondary to complex polygenic interactions that may lead to correspondingly complex patterns of inheritance. An alternative mechanism accounting for these sporadic cases may be de novo mutations occurring within germline or somatic cells that give rise to the atria.
A somatic mutation that develops within a myocardial progenitor cell will be absent from peripheral lymphocytes, precluding its detection on routine genetic testing. The resultant cardiac mosaicism, referring to the mutation being confined to a proportion of cells in the heart, has the potential to result in regional electric heterogeneity within the atria that could serve as an ideal substrate for the initiation and maintenance of AF. 17 Guided by this concept, investigators identified somatic mutations within connexin genes, the molecular constituents of gap junctions, in early onset, sporadic AF patients (n=15 and n=10) who had no evidence of structural heart disease or AF risk factors. 18, 19 Given the high yield of screening, the investigators hypothesized that cardiac mosaicism may be a common cause of sporadic AF within structurally normal hearts.
The advent of next-generation sequencing has revolutionized cancer diagnostics, a condition whose underlying pathophysiology is largely driven by somatic mutations. 20 Through the ability to rapidly screen large numbers of genes in a costeffective manner, next-generation sequencing has led to the identification of novel genetic culprits and has improved insight into the burden of somatic mutations within tumors. 21 Equally as important and in parallel with these technological advances, increasingly sophisticated probabilistic variant calling approaches have been developed to maximize sensitivity and specificity of detected variants. We sought to extend the use of these advances to the heart to evaluate the burden of atrial somatic mutations and investigate their potential impact on AF.
Methods

Study Population
Consecutive consenting adult patients aged ≥18 years undergoing cardiac surgery with left atrial appendage excision at Sutter Hospital, Sacramento Medical Center, were recruited between October 1, 2010, and November 1, 2012. Patients were excluded if they had congenital heart disease, any history of rheumatic valve disease, or mitral stenosis, if a right thoracotomy approach was used, if they were unable to provide informed and witnessed signed consent, or if they were pregnant or incarcerated. Participant demographics and medical details were obtained using a study questionnaire and were verified with a subsequent chart review. All study participants provided informed written consent under protocols that were approved by the University of California, San Francisco and Sutter Hospital, Sacramento, CA.
Custom-Targeted Genetic Panel
The genetic panel was designed to include all ion channels within the genome and genes previously implicated in Mendelian forms of cardiac disease as of November, 2013. The list of ion channels was constructed through a search of the Uniprot Knowledgebase using the terms ion channel and human. The 502 candidates were further manually curated to verify that the listed gene encoded an ion channel. This strategy led to the identification of 398 separate genes that were incorporated into the genetic panel ( Table I in the  Data Supplement) .
An additional 162 genes were selected based on their documented or potential involvement in primary cardiac disease ( Table I in the  Data Supplement) . We constructed this aspect of the genetic panel through a review of the genetic culprits associated with the following conditions: long QT syndrome, short QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, early repolarization syndrome, idiopathic ventricular fibrillation, arrhythmogenic right ventricular cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, left ventricular noncompaction, and mitochondrial cardiomyopathy. In addition, we included all genes implicated by proxy in the pathogenesis of AF from genome-wide association studies and other genes whose protein products have been implicated in the pathophysiology of the arrhythmia.
We extracted all known exons of the 560 genes using the Ensembl General Transfer Format (gtf) file annotating all transcripts in the human genome (release 68). To obtain exhaustive coverage of protein coding regions of genes of interest, a customized set of hybridization probes was designed and constructed using the Nimblegen SeqCap EZ Library kit (Roche NimbleGen, Madison, WI). In total, 3 218 095 of the 3 330 918 bases of interest were covered by ≥1 probes.
DNA and Library Preparation
Intraoperatively, left atrial appendage samples were immediately flash-frozen in liquid nitrogen in a sterile fashion. Genomic DNA was isolated from atrial tissue using the AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA). Matching lymphocyte DNA was purified from the buffy coat using the GentraPuregene Blood Kit (Qiagen) obtained from phlebotomy performed before surgery.
To generate sequencing libraries, 1 μg of DNA from each sample was randomly sheared to ≈200 base pairs using a Covaris S2 Ultrasonicator (Covaris, Woburn, MA). Subsequent library preparation was performed using the KAPA Library Preparation Kit (Kapa Biosystems, Wilmington, MA). Briefly, genomic DNA fragments were end-repaired and underwent A-tailing before adaptor ligation with 24 unique NEXTflex DNA Barcodes (Bioo Scientific, Austin, TX). Library enrichment was then performed through polymerase chain reaction amplification, followed by analysis of the size and quantity of ligated fragments using the Agilent 2100 Bioanalyzer (Santa Clara, CA). Recommended clean-up was performed at each step using Agencourt AMPure XP Beads (Beckman Coulter, Indianapolis, IN).
Targeted Gene Capture and Sequencing
The barcoded DNA library for each sample was then pooled with equal quantities of 23 other unique barcoded libraries to a total of 1 μg. The corresponding 24 NEXTflex DNA Barcode Blockers and COT human DNA were added to each pooled sample and then heat dried using a DNA vacuum concentrator. Hybridization of the genomic libraries with the custom-designed genetic panel was then performed consistent with manufacturer specifications.
After hybridization, the targeted fragments were pulled down and recovered using streptavidin-coupled dynabeads (Life Technologies, Grand Island, NY). Library enrichment and product analysis were repeated as detailed above. A total of 101 base pair paired-end sequencing was performed on an Illumina HiSeq 2500 sequencer with 24 samples to each lane of a flow cell. Samples were demultiplexed before analysis.
Analysis
The Burrows-Wheeler Aligner was used to align paired-end short reads to the human genome, whereas the Genome Analysis Toolkit was used for local realignment and recalibration. 22, 23 Sequencing quality metrics, including number of mapped reads, number of duplicate reads, and number of mappable bases were performed with samtools, Picard tools, and Genome Analysis Toolkit (Figures I and II in the Data Supplement). 23, 24 A total of 90 genes contained isolated base pair regions with inadequate coverage precluding reliable variant calling, collectively accounting for no >0.7% of the region of interest ( Figure III in the Data Supplement).
As a quality assurance measure, we compared single-nucleotide polymorphism (SNP) minor allele frequencies observed from our data with those from the 1000 Genomes CEU population. 25 We identified 2369 SNPs within our coverage area with minor allele frequency estimates of ≥5%. As inclusion of non-European individuals would generate inconsistent frequency estimates, we performed principal components analysis and removed 3 individuals based on the first principal component. Minor allele frequency estimates were generated using the remaining samples and plotted against 1000 Genomes CEU frequencies.
To improve variant calling, an estimate of cross-contamination of each sample was first obtained using the ContEst program ( Figure  IV in the Data Supplement). 26 Per sample estimates were then input into MuTect, allowing more accurate models for variant detection. MuTect is a state-of-the-art somatic mutation caller designed to maximize sensitivity and minimize the impact of technical sources February 2015 of false-positives. 27 The software program uses a probabilistic model to call differences based on number of reads, mapping quality, strand bias, and estimates of cross-contamination. Importantly, tumor and normal sources are analyzed in parallel, preventing the false-positives and false-negatives that typically arise from performing a post hoc comparison of variant files after variant calling has already been performed on the samples independently.
We applied the default MuTect parameters to identify potentially discordant variants between atrial and lymphocyte DNA. We observed that the overwhelming majority of variants that emerged from this analysis corresponded to G>T transversions ( Figure V in the Data Supplement). Low-level G>T transversions have become recognized as an important artifactual change that occurs with high coverage next-generation sequencing and are felt to arise secondary to oxidative damage that occurs during acoustic shearing of genomic DNA during sample preparation. 28 This oxidative damage occurs regardless of DNA source (ie, tissue versus lymphocyte). Although not an issue for germline mutation calling because of their trace quantities not being consistent with a heterozygous state, their low levels may be confused with somatic mutations. As a result, the recommended bioinformatic approach to G>T transversions within the cancer literature has been to filter them from the analysis given the overwhelming probability that they represent sequence artifacts. 28 Consistent with this methodologic approach, we also elected to filter G>T transversions from our analysis in an effort to minimize falsepositive findings.
Among the final discordant atrial variants, SnpEff (v. 3.3) was used to assess their impact on protein coding sequence. 29 Atriallymphocyte discordant variants expected to change protein sequence were further scrutinized with manual annotation, including examining their frequency in control populations, visualizing mapped reads, and analyzing whether the regions of interest map ambiguously in the genome. Discordant variants were also analyzed for their presence in multiple participants within the cohort and for evidence of occurrence in the reverse direction (absent in atrial cells and present within lymphocytes) among other members of the cohort, findings suggestive of systematic sequencing errors. A summary of our overall analytic approach to discordant variant calling is outlined in Figure 1 . Somatic fractions, defined as the percentage of total reads within an atrial sample, were determined for each remaining discordant atrial variant.
Attempted verification of potential discordant variants was pursued with Sanger sequencing of atrial DNA from relevant study participants. Amplification of targeted genomic regions was performed using polymerase chain reaction (primer sequences provided in the Data Supplement) followed by DNA sequencing using the ABI PRISM dye terminator method (Applied Biosystems, Foster City, CA).
Somatic Mutation Rate
Because of the sensitivity of the sequencing used, it is not possible to definitively distinguish potential false-positive discordant variants that pass through our filtering protocol from actual somatic mutations with low somatic fractions. To obtain a conservative estimate, we based our calculations of somatic mutation rates on the assumption that all possible somatic mutations that passed our a priori filtering processes were real. These rates were calculated by dividing the total number of somatic mutations by the total number of nucleotides examined in both AF cases and controls. The mean somatic mutation rate was reported as the number of somatic mutations per 100 million nucleotides.
Statistical Analysis
Normally distributed continuous variables are presented as mean±SD and the Student t test. Comparison of categorical values was performed using the χ 2 and Fisher exact tests. SNP minor allele frequencies within our cohort and the 1000 Genomes Project CEU subpopulation were compared using the Pearson pairwise correlation coefficient. To evaluate the possibility that filtering of G>T transversions may have resulted in a reduced sensitivity for detecting bona fide somatic mutations, we conducted a Monte Carlo simulation analysis to estimate the anticipated number of G>T transversions that would result in functional coding changes. Given that there are 12 nucleotide changes that could be observed for somatic mutations, with each assumed to be equally likely, we were able to generate a robust bootstrap estimate of the number of G>T changes expected under the assumption of no oxidative artifact. We used the total number of prefiltered observed changes (synonymous and nonsynonymous) as an empirical distribution and performed 10 000 random draws. For each draw and for each potential variant, we estimated a probability of missense mutation (using the observed missense rate and allowing some uncertainty) and totaled the result. A posterior mode and 95% credible interval were computed from the posterior distribution.
Two-tailed P values <0.05 were considered statistically significant. Statistical analyses were performed using Stata version 12 (College Station, TX, USA) and R. 
Results
Patient Characteristics
A total of 34 patients undergoing cardiac surgery with left atrial appendage excision at Sutter Hospital, Sacramento, provided both atrial tissue and peripheral blood for sequencing analysis. Twenty-five had a history of AF and 20 were undergoing cardiac surgery exclusively for a minimally invasive AF ablation. Among the participants with AF, the mean age at diagnosis was 63.0±11.9 years and 16 (64%) were men. Seventeen participants had AF in the absence of structural heart disease, 13 of whom had no family history of the arrhythmia. There were 11 individuals with AF in the absence of all known AF risk factors (including hypertension), 9 in the absence of a known family history. The remaining baseline characteristics of the participants are summarized in Table 1 . 
Next-Generation Sequencing
Analysis and Filtering Steps
Bioinformatic analysis using the somatic mutation caller MuTect initially identified 8710 discordant base calls when treating lymphocytes as the reference (germline) DNA source and atrial tissue as the somatic DNA source. Notably, 8604 (98.8%) of these discordant base calls represented G>T transversions, an aforementioned common source of artifactual DNA mutations arising secondary to oxidative damage during sample preparation. 28 No G>T transversions resulting in nonsynonymous missense mutations were observed within GJA1 or GJA5. Selective filtering of false-positive G>T transversions was precluded by the absence of previously reported contextual and strand bias. Monte Carlo simulation analysis revealed a 63% probability that none of the previously filtered G>T transversions reflected bona fide functional somatic mutations (95% confidence interval, 0-2; Figure VII in the Data Supplement). Classification of G>T transversions as false-positives reduced the list of discordant base calls to 106. From this list, an additional 5 were flagged by MuTect as having poor coverage and thus reduced reliability for variant calling.
Potential Atrial-Specific Variants
The above filters resulted in a total of 101 potential somatic atrial variants. A reverse analysis, treating atrial samples as reference and lymphocytes as the somatic tissue, revealed a comparable number (93) of variants. Within the overall list, 12 represented nonsynonymous SNPs predicted to impact the protein coding regions of a total of 11 genes. The remaining discordant base calls represented synonymous SNPs or were located within intronic regions.
Of the 12 potential nonsynonymous SNPs observed within atria and not in lymphocytes, an additional 7 were found to be consistent with sequencing artifact on the basis of their (1) being observed in multiple participants (a systematic error associated with the sequencing protocol was felt to be the likely explanation, particularly given that certain of these variants were present within highly repetitive regions of DNA prone to alignment errors); (2) being observed in the reverse direction (present within lymphocytes and absent from atrial cells) among other participants; and (3) having a >50% carrier frequency within the general population. The 5 remaining discordant genetic variants did not have population data frequency available indicating that they were either rare or novel ( Table 2 ). The discordant variants were carried by 3 of the 25 participants with AF and 2 were present within a single control participant with no prior history of the arrhythmia (12% versus 11%; P=1).
Somatic Fractions and Sanger Sequencing
The somatic fractions, defined as the percentage of total reads within the relevant atrial sample, for the 5 remaining potential nonsynonymous cardiac somatic mutations ranged from 2.3% to 7.3%. Sanger sequencing of atrial samples from each patient carrying a potential discordant variant yielded electropherograms with no evidence of a somatic mutation (Figure 3 ).
Somatic Mutation Rate
Among the 25 AF cases, there were 3 potential somatic mutations and an average of 3.25 million mapped base pairs per sample corresponding to an average somatic mutation rate of 4 per 100 million nucleotides (range, 0-31; SD, 10). A total of 2 potential somatic mutations were observed among the 9 control participants, and the average mapped base pairs per sample was also 3.25 million. This yields an average somatic mutation rate among controls of 7 per 100 million (range, 0-62; SD, 21). 
Discussion
Our next-generation sequencing study targeting 560 genes found no evidence to support a role for somatic mosaicism in the pathogenesis of AF among 25 affected patients (17 with no structural heart disease and 11 with no AF risk factors including hypertension) and 9 control participants. Our study screening for atrial somatic mutations is the largest to date and is the first to assess a large number of genes. We found no missense somatic mutations within the GJA5 and GJA1 genes and no difference in the frequency of potential somatic mutations between AF cases and controls within our cohort (12% versus 11%; P=1). Our findings also suggest that atrial somatic mutations are rare, further reinforcing the notion that atrial mosaicism exerts a minimal role in AF pathogenesis.
Our findings contrast with previous work suggesting that ≈20% of nonfamilial AF occurring in the absence of structural heart disease may be secondary to somatic mutations within GJA5 and GJA1, encoding connexin 40 and 43, respectively. 18, 19 Given a ≈20% yield from screening just 2 genes, it was reasonable to speculate that somatic mosaicism may reflect a common underlying pathophysiology in AF with important clinical implications. In addition to failing to detect any evidence of somatic mutations within either GJA5 or GJA1, the overall somatic mutation rate among AF cases in our study was also low (4 per 100 million nucleotides). We found only 3 discordant atrial-lymphocyte genetic variants projected to result in functional changes and each had a low atrial somatic fraction. Notably, none could be confirmed by traditional Sanger sequencing. Indeed, even if real, it is unclear whether such low somatic fractions (from 2.3% to 7.3%) would have any meaningful clinical relevance. These findings argue that atrial mosaicism is unlikely to exert a prominent role in AF pathophysiology.
There are 2 possible explanations for the contrasting results between the current and previous studies, namely patient selection and sequencing artifact secondary to formalin fixation. In both previous connexin studies, the investigators restricted their cohort to individuals with early onset (age <55 years), sporadic AF. 18, 19 The mean age at AF diagnosis in the GJA5 study was 45.1±5.9 years and patients were free of comorbidities, whereas our AF cohort was older (63.0±11.9 years), ≈50% had hypertension, and 7 of the 25 study participants with AF had an affected family member. It is conceivable that the selection criteria for the previous cohorts may have resulted in patients who had a higher burden of atrialspecific mutations within cardiac genes.
Patient selection alone, however, is unlikely to account for our discordant findings in relation to the prior AF somatic mutation reports. The previously reported high rate of atrial somatic mutations was likely affected by polymerase chain reaction artifacts after DNA extraction from formalin-fixed paraffin-embedded tissue. 30 A growing number of articles within the oncology literature have warned about the potential for erroneously identifying somatic mutations in tumor samples previously fixed with formalin. [30] [31] [32] [33] Within the field of cardiology, initial reports suggesting that NKX2-5 somatic mutations were a common cause of congenital heart disease were subsequently shown to likely reflect false-positives secondary to formalin fixation. [34] [35] [36] Of note, our atrial DNA samples were obtained from tissue that was flash-frozen immediately after excision, whereas the previous connexin mutations were identified after DNA extraction from formalin-fixed and paraffin-embedded left atrial appendage tissue. 18, 19 Despite the apparent overestimation of the role of atrial-specific connexin mutations in AF, it should be noted that the reported atrial somatic GJA1 mutation has also been reported as a somatic mutation from a flash-frozen gastrointestinal tumor source. 37 It is also important to emphasize that these somatic mutations were described alongside the first connexin germline mutation associated with AF, findings subsequently substantiated by the role of rare connexin 40 mutations in familial AF. 38, 39 Although it is conceivable that our bioinformatic methods for detecting somatic mutations with next-generation sequencing may have underestimated their true prevalence, it should be noted that the approach used has been validated extensively and shown to have extremely high sensitivity and specificity. 20, 40, 41 At our median sequencing depth (265-fold), the estimated sensitivity for detecting somatic mutations with an atrial somatic fraction of 10% is 99.999%. When the atrial somatic fraction drops to 5%, 2%, and 1%, our sensitivity for detection correspondingly falls to 99.2%, 76.8%, and 26.9%, respectively. 27 These sensitivity estimates far exceed those for Sanger sequencing, the approach used for identifying the previous somatic mutations in AF patients. The atrial somatic fractions for the previously documented GJA5 and GJA1 somatic mutations implicated in AF were estimated to range from 20% to 34% based on the results of allelic subcloning. 18, 19 Given our anticipated sensitivity, it is unlikely that we failed to detect somatic mutations with atrial somatic fractions in that range.
The challenges of recognizing artifactual mutations in previous small-scale studies highlight one of the main strengths of our study: the analysis of an unprecedented number of bases within multiple genes across multiple affected and control individuals. Focus on a small number of genes or samples would have failed to detect systematic biases, such as the G>T oxidative changes, or sample cross-contamination, and these would have been erroneously interpreted as somatic mutations. In addition, the availability of control samples allowed filtering of recurrent artifactual mutations that likely arise from alignment errors. In fact, the somatic mutation calling pipeline of most large tumor sequencing centers includes a critical filtering step whereby all variants previously observed in a large panel of hundreds of control samples are removed, as these are likely to represent artifact arising from ≥1 steps in the variant calling process. 42 The absence of evidence to support a role for atrial somatic mutations in AF within our cohort should not be viewed as evidence to completely rule out somatic mosaicism as a pathophysiological mediator of AF. Although our results suggest that such a mechanism is likely rare, at least 1 other study identified a potential disease-causing somatic mutation in an arrhythmic disease. 43 However, our results suggest that the vast majority of cases of sporadic, AF occurring in the absence of overt cardiovascular disease develop secondary to either another genetic mechanism or some as yet unknown exposure. Because this form of AF accounts for ≤30% of all AF cases and the majority seem to be sporadic, these patients comprise a substantial number in the population. 16, 44 Furthermore, because understanding the pathogenesis of the disease in these individuals should uncover mechanisms unique to AF itself (rather than simply an AF risk factor, such as congestive heart failure), it is critical to assure that research efforts are on the right track. Therefore, although our results are negative, we think that this comprehensive investigation is sufficiently robust to steer the field toward examining novel polygenic or gene-environment interactions, as well as potential behaviors or environmental influences that may be important.
Limitations
Although our study examining for atrial somatic mutations involves both the largest number of patients and genes tested to date, our cohort size of 25 AF patients and 9 controls is still modest. In addition, our bioinformatic methods for identifying somatic mutations with next-generation sequencing, although highly sensitive and state-of-the-art, could potentially have failed to identify bona fide atrial somatic mutations (particularly those with an atrial somatic fraction <2% when our sensitivity is estimated to drop <95% given our median 265-fold coverage depth). Although the frequency of potential somatic mutations was similar in both cases and controls, we cannot exclude the possibility that the discordant variants among the AF cases were pathogenic, whereas those in controls were benign. Finally, although our genetic panel covered >3 million base pairs and an exhaustive number of genes related to cardiac pathophysiology (including the genes previously implicated in somatic mutations), it remains possible that genetic mosaicism involving undiscovered variants related to AF could yet be important. We chose to restrict our analysis to 560 genes to assure high-depth coverage, thereby maximizing our sensitivity and specificity for accurately identifying somatic mutations.
Conclusions
Using high-depth next-generation sequencing and state-of-the art somatic mutation identification approaches, we found no evidence to support a role for pathogenic atrial somatic mutations in AF using a comprehensive cardiac genetic arrhythmia panel. These findings indicate that atrial-specific mutations are rare and suggest that somatic mosaicism likely exerts a minimal role in the pathogenesis of AF.
